| abstract |
[1,2,4] Triazolo [1,5-a] pyridine compounds having the formula represented by the formula (I) are described. The compounds can be prepared as pharmaceutical compositions, and can be used for the prevention or treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, diseases involving cartilage degradation, bone and / or joint degradation, by example osteoarthritis; and / or conditions that involve inflammation or immune response, such as Crohn's disease, rheumatoid arthritis, psoriasis, allergic airway disease, (eg, asthma, rhinitis), juvenile idiopathic arthritis, colitis, inflammatory bowel diseases, conditions of endotoxin-driven disease (for example, complications after baipás surgery or chronic endotoxin states that contribute to, for example, chronic heart failure), diseases that involve dysfunction of cartilage functionality (for example, diseases that involve anabolic chondrocyte stimulation), congenital cartilage malformations, diseases associated with hypersecretion of 1L6 and transplant rejection (for example, organ transplant rejection) and proliferative diseases. |